Search results
Showing 121 to 135 of 168 results for fibrosis
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
We have moved Medical technologies guidance 27 to become HealthTech guidance 385. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]
Discontinued Reference number: GID-TA11262
from guidance Mannitol dry powder for inhalation for treating cystic fibrosis Number TA266 Date issued November 2012 Other
Discontinued Reference number: GID-TA10390
Faltering growth: recognition and management of faltering growth in children (NG75)
This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
In development Reference number: GID-TA11352 Expected publication date: TBC
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.